
Opinion|Videos|August 30, 2024
Influences and Challenges of Biomarkers on Treatment Selection
The key opinion leaders explore various treatment approaches for prostate cancer, including surgery, radiation, and hormone therapy, explaining how biomarker results influence their treatment choices. They also detail the specific criteria they use to select between treatment options based on biomarker testing outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please discuss different treatment approaches (e.g. surgery, radiation, hormone therapy) and how biomarkers may have influenced your choice.
- What criteria do you use to decide between treatment options based on biomarker testing results?
- What challenges and/or barriers have you encountered when selecting a biomarker?
- Is there one that you use for a specific patient population?
Advertisement
Related to this article

Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.

The phase 1/2 ARGATE-001 trial will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer.

Moderators in 4 forums reviewed ARANOTE, ARACOG, and ARASEC data and discussed what differentiates doublet options in mCSPC.

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
2
LIB-01 enters phase 2b development for erectile dysfunction
3
Prostate Cancer, BPH, and Testosterone Scheduling Myths
4
The evolving role of urology APPs: From follow-up care to clinical leadership
5





